James Murrough
Professor of Psychiatry and Clinical Researcher
Data updated
Research Footprint
James Murrough appears in 19 tracked papers (2012–2024), most studied alongside Ketamine, Placebo and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial (1200 citations).
Frequent co-authors: Dennis Charney, Daniel Iosifescu and Sanjay Mathew.
Publication Landscape
How the 19 papers Blossom tracks for James Murrough line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has James Murrough's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 19 of 19 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does James Murrough publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does James Murrough publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
James W. Murrough, MD, PhD, is a clinician–scientist specialising in mood and trauma-related disorders with a sustained programme of translational clinical research. He has led multiple randomised controlled trials and early-phase studies investigating intravenous and intranasal ketamine for treatment-resistant major depression and post-traumatic stress disorder, and has participated in early human work on other psychoactive compounds. Murrough's work bridges clinical trials, biomarker and neuroimaging studies, and systematic evidence syntheses to clarify both efficacy and underlying neurobiological mechanisms of rapid-acting antidepressant treatments.
Affiliated with academic medical centres and Veterans Affairs research programmes, Murrough has contributed important multicentre and dose/frequency studies, examined repeated-administration strategies for chronic conditions, and helped integrate findings from clinical trials into broader discussions of psychedelic-assisted psychotherapy and emerging pharmacotherapies. His research has informed clinical practice, trial design, and ongoing efforts to identify predictors and moderators of treatment response for novel neuropsychiatric interventions.
Key Impact
A leading clinician-scientist who has advanced the clinical development and mechanistic understanding of ketamine and related rapid-acting interventions for treatment-resistant mood and trauma-related disorders.
Collaboration Network
37 collaborators· click a node to visit their profile
Full network →Collaboration Network
See James Murrough's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations James Murrough is associated with.